Blood molybdenum level as a marker of cancer risk on BRCA1 carriers

Elevated blood molybdenum levels are associated with an increased risk of ovarian cancer on BRCA1 mutation carriers. Lowering molybdenum levels may potentially reduce cancer risk in this population, and high molybdenum levels could serve as a marker for considering preventive oophorectomy in BRCA1 carriers. Further research is warranted to confirm these findings and explore interventions targeting molybdenum levels as a preventive measure for ovarian cancer in BRCA1 mutation carriers.

Authors

Institutions

Publication Details

Journal
Hereditary Cancer in Clinical Practice
Published
2024-09-19
DOI
https://doi.org/10.1186/s13053-024-00291-7
Citations
4
Primary Topic
RNA modifications and cancer
Type
article
Field-Weighted Citation Impact
0.94
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Blood molybdenum level as a marker of cancer risk on BRCA1 carriers

Monika Siołek, Róża Derkacz, Małgorzata Stawicka-Niełacna, Adam Kiljańczyk et al.
4 citations
Hereditary Cancer in Clinical Practice
RNA modifications and cancer
0.94
article

Blood molybdenum level as a marker of cancer risk on BRCA1 carriers

Monika Siołek, Róża Derkacz, Małgorzata Stawicka-Niełacna, Adam Kiljańczyk, Tomasz Huzarski, Wojciech Marciniak, Dariusz Godlewski, Marta Bryśkiewicz, Marcin Lener, Renata Posmyk, Joanna Jarkiewicz‐Tretyn, Artur Prusaczyk, Milena Matuszczak, Joanna Tomiczek‐Szwiec, Piotr Baszuk, Sandra Pietrzak, Tomasz Kluz, Klaudia Stempa, Steven A. Narod, Jacek Gronwald, Ewa Kilar-Kobierzycka, Andrzej Jasiewicz, Jan Lubiński, Cezary Cybulski, Anna Jakubowska, Tadeusz Dębniak, Marek Szwiec, Rodney Scott
article en
4 citations

Abstract

Elevated blood molybdenum levels are associated with an increased risk of ovarian cancer on BRCA1 mutation carriers. Lowering molybdenum levels may potentially reduce cancer risk in this population, and high molybdenum levels could serve as a marker for considering preventive oophorectomy in BRCA1 carriers. Further research is warranted to confirm these findings and explore interventions targeting molybdenum levels as a preventive measure for ovarian cancer in BRCA1 mutation carriers.

Hereditary Cancer in Clinical PracticeVol. 22(1)
Medical University of Białystok (PL), Kazimierz Wielki University in Bydgoszcz (PL), University of Opole (PL), University of Siedlce (PL), John Hunter Hospital (AU), Hunter Medical Research Institute (AU), Holy Cross University (PL), Cancer Genetics (United States) (US), International Hereditary Cancer Center (PL), Read-Gene (Poland) (PL), University of Zielona Góra (PL), Pomeranian Medical University (PL), University of Rzeszów (PL)
Good health and well-being
Openalex Percentile: Top 25%
RNA modifications and cancer
0.94
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.